‘Yoga paves the way for welfare of the world and discipline of the body'
International Yoga Day
, the
BJP
organised yoga functions at the division and booth levels across the state. At the state party headquarters, the yoga function was headed by BJP national co-organisational general secretary Shivprakash, chief minister Mohan Yadav, BJP state president Vishnudutt Sharma, and state party organisational general secretary Hitanand Sharma.
Office-bearers and party workers performed yoga in the early morning hours.
Addressing the workers, Shivprakash said that yoga is not just a physical exercise, but an art of living. "Samatvam Yoga Uchyate" means that the essence of yoga is equanimity; to see every person and situation of the world with an equal perspective. This equanimity brings balance and stability in life.
"Those with a liberal outlook consider the entire world as their family.
This is the basic thought of Indian culture, to rise above conflict, exploitation, and war and move towards the welfare of all. Yoga paves the way for the welfare of the world along with the discipline of the body," the BJP national co-organisational general secretary said.
CM Mohan Yadav said that yoga is such a divine state when consciousness and supreme consciousness meet. Every living being has the opportunity to achieve this state of mind.
Yoga is an invaluable gift of Sanatan Hindu religion and culture to the entire humanity. "Due to the tireless efforts of PM Modi, UNGA declared June 21 as International Yoga Day," he said. "It also supported the fact that yoga provides a holistic approach to health and well-being along with establishing a balance between all aspects of life.
He ushered in a new era of holistic health revolution across the world. Today, the entire global community is expressing gratitude to Prime Minister Modi. We are celebrating the 11th International Yoga Day. It is dedicated to the theme of Yoga for One Earth, One Health," Yadav said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
22 minutes ago
- The Hindu
AINU launches new centre in Hyderabad covering various sub-specialities
The Asian Institute of Nephrology and Urology (AINU), launched its new centre in Banjara Hills here on Monday. The hospital has a capacity of 150 beds. The centre features four operating rooms, 34 dialysis stations and advanced robotic surgical technology, enabling complex urology and nephrology procedures with greater precision. The hospital also has eight centres of excellence, covering sub-specialities such as female urology, uro-oncology and robotic surgery, paediatric urology, reconstructive urology and andrology. The burden of urological diseases is rising sharply in India due to lifestyle disorders such as hypertension, obesity and diabetes, coupled with increased life expectancy. 'Prostate cancer is now the second most common cancer among Indian men, growing at 2.5% annually, and 50 to 60% of men over 60 suffer from benign prostatic enlargement,' said AINU manging director Mallikarjuna. He added that 25 years ago, urology was largely limited to treating kidney stones and enlarged prostates. Today, the scope includes advanced cancer care, complex reconstructions, paediatric interventions, female urology and robotic surgeries. 'One doctor cannot be perfect in every area, so we have created dedicated teams focused solely on one sub-speciality, performing the same surgeries repeatedly. This results in faster procedures, fewer complications, better outcomes and ultimately lower costs for patients,' he added.
Economic Times
an hour ago
- Economic Times
India clears Roche's 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
Synopsis Roche has received clearance to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration in India, potentially reducing cancer treatment time and costs. The approval, granted by a technical committee, requires Roche to conduct a Phase IV clinical trial in India. This new route offers a faster, more convenient option for patients, with administration possible outside of hospitals. Roche Gets Approval to Import Key Cancer Injection for Domestic Mkt New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection (Tecentriq) through subcutaneous (SC) route-under the skin injection for Indian decisions is expected to provide relief to patients in the contry as the new subcutaneous injections will cut treatment time to nearly seven minutes from the 30-60 minutes in the standard intravenous (IV) infusion, besides saving on costs. The panel's permission has been given with a condition that the company would conduct a Phase IV clinical trial in India. "Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official told ET. "Tecentriq may be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home," he added. Atezolizumab is an immunotherapy called an immune checkpoint inhibitor, which blocks the immune system's natural brakes to help immune cells fight technical committee under the Director General of Health Services (DGHS) was formed in 2013 following the directions of the Supreme a recent meeting, Roche presented the proposal for grant of permission to import and market the drug product Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration for the following indications with the request of local Phase III clinical trial waiver and commitment to conduct a Phase IV trial in is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. It is a monotherapy for the first line treatment of patients of metastatic committee noted the pharmacokinetic-pharmacodynamic or PK/PD results of Asian & non-Asian population from the global clinical study for the ethnic differences in the PK parameters in the study. The committee further noted that firm has received the USFDA approval for the SC route on committee also asked the company to submit Phase IV clinical trial protocol to CDSCO within three months of grant of marketing authorisation.
Time of India
an hour ago
- Time of India
India clears Roche's 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection ( Tecentriq ) through subcutaneous (SC) route-under the skin injection for Indian patients. The decisions is expected to provide relief to patients in the contry as the new subcutaneous injections will cut treatment time to nearly seven minutes from the 30-60 minutes in the standard intravenous (IV) infusion, besides saving on costs. The panel's permission has been given with a condition that the company would conduct a Phase IV clinical trial in India. "Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official told ET. "Tecentriq may be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home," he added. Atezolizumab is an immunotherapy called an immune checkpoint inhibitor, which blocks the immune system's natural brakes to help immune cells fight cancer. The technical committee under the Director General of Health Services (DGHS) was formed in 2013 following the directions of the Supreme Court. In a recent meeting, Roche presented the proposal for grant of permission to import and market the drug product Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration for the following indications with the request of local Phase III clinical trial waiver and commitment to conduct a Phase IV trial in India. Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. It is a monotherapy for the first line treatment of patients of metastatic NSCLC. The committee noted the pharmacokinetic-pharmacodynamic or PK/PD results of Asian & non-Asian population from the global clinical study for the ethnic differences in the PK parameters in the study. The committee further noted that firm has received the USFDA approval for the SC route on 12.09.2024. The committee also asked the company to submit Phase IV clinical trial protocol to CDSCO within three months of grant of marketing authorisation.
